BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15879783)

  • 1. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.
    Pelzer A; Bektic J; Berger AP; Pallwein L; Halpern EJ; Horninger W; Bartsch G; Frauscher F
    J Urol; 2005 Jun; 173(6):1926-9. PubMed ID: 15879783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels.
    Yang JC; Tang J; Li J; Luo Y; Li Y; Shi H
    Acad Radiol; 2008 Oct; 15(10):1291-7. PubMed ID: 18790401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy.
    Yokomizo Y; Miyoshi Y; Nakaigawa N; Makiyama K; Ogawa T; Yao M; Kubota Y; Uemura H
    Urol Int; 2009; 82(3):280-5. PubMed ID: 19440014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection.
    Mitterberger M; Horninger W; Pelzer A; Strasser H; Bartsch G; Moser P; Halpern EJ; Gradl J; Aigner F; Pallwein L; Frauscher F
    Prostate; 2007 Oct; 67(14):1537-42. PubMed ID: 17705242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less.
    Aigner F; Pallwein L; Junker D; Schäfer G; Mikuz G; Pedross F; Mitterberger MJ; Jaschke W; Halpern EJ; Frauscher F
    J Urol; 2010 Sep; 184(3):913-7. PubMed ID: 20643432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening project.
    Pelzer AE; Bektic J; Berger AP; Halpern EJ; Koppelstätter F; Klauser A; Rehder P; Horninger W; Bartsch G; Frauscher F
    Eur Urol; 2005 Dec; 48(6):916-21; discussion 921. PubMed ID: 16126324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection.
    Naughton CK; Miller DC; Mager DE; Ornstein DK; Catalona WJ
    J Urol; 2000 Aug; 164(2):388-92. PubMed ID: 10893592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling.
    Taverna G; Morandi G; Seveso M; Giusti G; Benetti A; Colombo P; Minuti F; Grizzi F; Graziotti P
    BJU Int; 2011 Dec; 108(11):1723-7. PubMed ID: 21756276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prostate cancer detection by prostate biopsy among Japanese with prostate-specific antigen below 4.0 ng/ml].
    Kanno T; Shibasaki N; Tsuji Y; Taki Y; Takeuchi H
    Hinyokika Kiyo; 2006 Mar; 52(3):181-4. PubMed ID: 16617870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
    Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficiency of contrast-enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection.
    Mitterberger MJ; Aigner F; Horninger W; Ulmer H; Cavuto S; Halpern EJ; Frauscher F
    Eur Radiol; 2010 Dec; 20(12):2791-6. PubMed ID: 20571801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
    Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
    Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels.
    Pelzer AE; Volgger H; Bektic J; Berger AP; Rehder P; Bartsch G; Horninger W
    BJU Int; 2005 Nov; 96(7):995-8. PubMed ID: 16225515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-enhanced colour Doppler-targeted prostate biopsy: correlation of a subjective blood-flow rating scale with the histopathological outcome of the biopsy.
    Mitterberger M; Aigner F; Pinggera GM; Steiner E; Rehder P; Ulmer H; Halpern EJ; Horninger W; Frauscher F
    BJU Int; 2010 Nov; 106(9):1315-8; discussion 1318. PubMed ID: 20346032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
    Uemura H; Nakamura M; Hasumi H; Sugiura S; Fujinami K; Miyoshi Y; Yao M; Kubota Y
    Int J Urol; 2004 Jul; 11(7):494-500. PubMed ID: 15242358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
    Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
    Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.
    Inahara M; Suzuki H; Kojima S; Komiya A; Fukasawa S; Imamoto T; Naya Y; Ichikawa T
    Urology; 2006 Oct; 68(4):815-9. PubMed ID: 17070359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
    Eggener SE; Roehl KA; Catalona WJ
    J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
    Park HK; Hong SK; Byun SS; Lee SE
    Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.